1 
References 
1. Thomas ED: Marrow transplantation for acute leukemia. Cancer 42: 895-900, 1978. 
2. Meyers JD: Infection in recipients of marrow transplants. Chapter 6. In: Remington JS, 
Swartz MN, (eds.). Current ainical Topics in Infectious Diseases. New York: 
McGraw-Hill, p. 261-292, 1985. 
3. van der Meer JWM, Guiot HFL, van den Broek PJ, van Furth R: Infections in bone 
marrow transplant recipients. Semin Hematol 21: 123-140, 1984. 
4. Buckner CD, Clift RA, Sanders JE, Meyers JD, Counts GW, Farewell VT, Thomas ED, 
The Seattle Marrow Transplant Team: Protective environment for marrow transplant 
recipients. A prospective study. Ann Intern Med 89: 893-901, 1978. 
5. Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H-S, Thomas 
PRM, Glasgow GP, Shina DC, Herzig GP: Treatment of resistant malignant lymphoma 
with cyclophosphamide, total body irradiation, and transplantation of ciyopreserved 
autologous marrow. N Engl J Med 310: 1557-1561, 1984. 
6. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast 
RC Jr, Gilbert CJ, Oette DH: Effect of recombinant human granulocyte-macrophage 
colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy 
and autologous bone marrow transplantation. N Engl J Med 318: 869-876, 1988. 
7. Nemunaitis J, Singer JW, Buckner CD, Hill R, Storb R, Thomas ED, Appelbaum FR: 
Use of recombinant human granulocyte-macrophage colony-stimulating factor in 
autologous marrow transplantation for lymphoid malignancies. Concise Report Blood 
72: 834-836, 1988. 
8. Nemunaitis J, Singer JW, Buckner CD, Epstein C, Hansen J, Hill R, Storb R, Thomas 
ED, Appelbaum FR. Preliminary analysis of a randomized, placebo-controlled trial of 
rhGM-CSF in autologous bone marrow transplantation (ABMT). AS CO (Abstract), 
1990. 
9. Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A, Shimosaka A, 
Shibata H, Nakamura H: Recombinant human granulocyte colony-stimulating factor in 
allogeneic bone marrow transplantation. Exp Hematol 17: 1047-1050, 1989. 
10. Taylor K, Spitzer G, Jagannath S, Dicke K, Souza L: Phase II study of recombinant 
human granulocyte colony-stimulating factor (rhG-CSF) in Hodgkin’s disease after 
high-dose chemotherapy with ABMT. Blood 72(SuppLl): 135a, 1988. (abstr.) 
11. Oppenheim JJ, Neta R, Tiberghien P, Gress R, Kenny JL, Longo DL: Interleukin-1 
enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. 
Blood 74: 2257-2263, 1989. 
12. Sandoz Pharmaceuticals Corporation Research Data. 
13. Monroy RL, Davis JA, Donahue RE, MacVittie TJ: Collection of enriched PBSCs 
from primates treated with ELI and IL3 in vitro. (Abstract) Blood 74: 75a, 1989. 
14. Donahue RE, Seehra J, Metzger M, Lefebvre D, Rock B, Carbone S, Nathan DG, 
Gamick M, Sehgal PK, Laston D, LaVallie E, McCoy J, Schendel PF, Norton C, Turner 
K, Yang Y-C, Qark SC: Human IU3 and GM-CSF act synergistically in stimulating 
hematopoiesis in primates. Science 241: 1820-1823, 1988. 
Krumwieh D, Seiler FR: In vivo effects of recombinant colony stimulating factors on 
[336] 
Recombinant DNA Research, Volume 16 
